Arcutis Biotherapeutics, Inc. (ARQT) - Dilution Analysis

10-Q filing | 125.1M shares outstanding

10-Q filing | 126.0M shares outstanding

10-K filing | 121.0M shares outstanding

10-Q filing | 124.3M shares outstanding

10-Q filing | 123.5M shares outstanding

10-Q filing | 111.0M shares outstanding

10-K filing | 96.8M shares outstanding

S-3 filing: This is an S-3 filing for an at-the-market offering of common stock through TD Cowen. The offering price per share may exceed the net tangible book value per share of common stock outstanding. The number of shares sold will fluctuate based on the market price and limits set with TD Cowen.

10-Q filing | 94.4M shares outstanding

8-K filing: Arcutis Biotherapeutics, Inc. entered into an underwriting agreement for a public offering of 32,500,000 shares of common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, with an option for the underwriters to purchase up to 6,000,000 additional shares. ($93.5M proceeds)

10-Q filing | 61.4M shares outstanding

10-Q filing | 61.2M shares outstanding

10-K filing | 55.0M shares outstanding

10-Q filing | 57.1M shares outstanding

8-K filing: Arcutis Biotherapeutics, Inc. completed a public offering of 7,500,000 shares of common stock at $20.00 per share, and the underwriters exercised their option to purchase an additional 1,125,000 shares, resulting in net proceeds of approximately $161.7 million. ($172.5M proceeds)

10-Q filing | 51.4M shares outstanding

10-Q filing | 50.5M shares outstanding

10-K filing | 49.4M shares outstanding

10-Q filing | 50.1M shares outstanding

10-Q filing | 50.0M shares outstanding

10-Q filing | 50.2M shares outstanding

10-K filing | 50.1M shares outstanding

10-Q filing | 43.6M shares outstanding

8-K filing: Arcutis Biotherapeutics, Inc. closed its underwritten public offering of 4,000,000 shares of common stock at $25.00 per share and concurrently closed a private placement with OrbiMed Affiliates for $35.0 million of common stock at $25.00 per share, generating net proceeds of approximately $128.5 million. ($135.0M proceeds)

S-1 filing: This is an S-1 filing for an initial offering of common stock, including an option to purchase additional shares and a concurrent private placement. Proceeds from the offering will fund continued development of programs, commercial launch planning, and general corporate purposes.

10-Q filing | 38.2M shares outstanding

10-Q filing | 38.2M shares outstanding

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with an option to purchase additional shares, and indications of interest from existing stockholders. The company intends to use the net proceeds from this offering to fund the further development of ARQ-151, ARQ-154 and ARQ-252, for working capital and general corporate purposes.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.